Drug Profile

ZE 74 0282

Alternative Names: ZE 74-0282

Latest Information Update: 14 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eilean Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action Janus kinase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Myeloproliferative disorders; Polycythaemia vera
Discontinued Cancer

Most Recent Events

06 Nov 2025 Discontinued - Preclinical for Cancer in USA (unspecified route)
06 Nov 2025 Pharmacodynamics data from a preclinical trials in Polycythaemia vera and Myeloproliferative disorders released by Eilean Therapeutics
06 Nov 2025 Eilean Therapeutics plans a first-in-human clinical trial for myeloproliferative disorders and polycythaemia vera in in December 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com